Ferrara et al. did not observe any association between hyperprogression and age (with 46% of patients older than 65 years old), tumoral PD-L1 status, molecular status including EGFR alterations, previous treatments, type of ICI (anti-PD-1 vs. anti-PD-L1), and ECOG status among 406 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors [18]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.